Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.254
+0.003 (1.23%)
At close: Mar 9, 2026, 4:00 PM EDT
0.251
-0.003 (-1.22%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,752,444
Market Cap
11.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| Imunon | 25 |
| BiomX | 20 |
| BioCardia | 20 |
| Soligenix | 16 |
| CalciMedica | 15 |
| Cellectar Biosciences | 11 |
AKTX News
- 11 days ago - Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - GlobeNewsWire
- 19 days ago - Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - GlobeNewsWire
- 26 days ago - Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript - Seeking Alpha
- 26 days ago - Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire
- 6 weeks ago - Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - GlobeNewsWire
- 2 months ago - Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewsWire
- 2 months ago - Akari Therapeutics to Present at the 2026 Biotech Showcase - GlobeNewsWire